Detalhe da pesquisa
1.
Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Haematologica
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38426294
2.
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Hematology
; 28(1): 2156731, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36607147
3.
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
J Manag Care Spec Pharm
; 29(11): 1205-1218, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776124